Manufacturer record
Unigrow Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Unigrow Pharmaceuticals (Himachal Pradesh) were declared Not of Standard Quality between July 2024 and April 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: UGT24G06A, Telmisartan & Amlodipine Tablets IP (exp Sep 2026). DTL Thiruvananthapuram (state lab) found it not of standard quality: It fails the tests for ?Assay? of Amlodipine and ?Dissolution? as specified in the Laboratory Protocol as per IP. Listed in the April 2025 alert.
Records by type
2 records linked to Unigrow Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Telmisartan & Amlodipine Tablets IP | Batch UGT24G06AMfg Oct 2024 · Exp Sep 2026 | It fails the tests for ?Assay? of Amlodipine and ?Dissolution? as specified in the Laboratory Protocol as per IPAssay | DTL ThiruvananthapuramState lab | Apr 2025 |
| Ofloxacin & Ornidazole Tablets IP (Samri-OZ) | Batch UGT23J14AMfg Jan 2023 · Exp Dec 2024 | Dissolution & AssayAssay | CDL KolkataCDSCO lab | Jul 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.